 BOSTON, Aug. 07, 2020 GLOBE NEWSWIRE -- Imara Inc. Nasdaq: IMRA, a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, August 14, 2020, at 8:30 a.m. ET to discuss its second quarter 2020 financial results and other business updates. A live webcast will be available under Events and Presentations in the Investors section of the companys website at imaratx.com. The conference call can be accessed by dialing 1 833 519-1307 U.S. domestic or 1 914 800-3873 international and referring to conference ID 9775635. A replay of the webcast will be archived on the Imara website following the presentation.About Imara Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit Contact: Michael Gray 617-835-4061 